Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07192614 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

A Phase 1 study of Prostate Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
52
Enrollment target
18
Study locations

NCT07192614 is a Phase 1 study of Prostate Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 52 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower). The trial reports 18 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07192614, a Phase 1 study of Prostate Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
52 participants
Enrollment target
18
Study locations

Study Summary

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels of AZD6621 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD6621 doses in a larger group of participants (dose expansion).

Conditions Studied

Prostate Cancer

Interventions

  • DRUG AZD6621

Study Locations (18)

Other

  • Research Site - Ghent
  • Research Site - Beijing
  • Research Site - Guangzhou
  • Research Site - Nanjing
  • Research Site - Chūōku
  • Research Site - Hirakata-shi
  • Research Site - Kashiwa
  • Research Site - Amsterdam
  • Research Site - Maastricht
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Cambridge

Florida

  • Research Site - Orlando
  • Research Site - Tampa

Massachusetts

  • Research Site - Boston

Michigan

  • Research Site - Grand Rapids

New York

  • Research Site - Commack

Rhode Island

  • Research Site - Providence

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2025-09-30
Est. Completion 2029-03-29
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07192614

The ClinicalTrials.gov registry entry for NCT07192614 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which AZD6621 is the first listed.

NCT07192614 reports 18 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07192614 about?

NCT07192614 is a clinical study titled "A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer". This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study is also further spl...

What is the current status of trial NCT07192614?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2025-09-30. Estimated completion is 2029-03-29.

What conditions does trial NCT07192614 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT07192614?

The interventions under investigation include: AZD6621 (DRUG).

Who is sponsoring clinical trial NCT07192614?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07192614 being conducted?

This trial has 18 study locations across Florida, Massachusetts, Michigan, New York, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.